XBI241122P88000
- 0.35
- -0.20-36.36%
SPDR S&P Biotech ETF Newsroom
26 Analysts Assess Gilead Sciences: What You Need To Know
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Gilead Sciences Analyst Ratings
Daily options tracking | Trump's assistance? Tesla rose more than 8% in pre-market trading, with a large single l bet on the rise last Friday; Palantir hit a new all-time high! Multiple call options made over 9 times profit.
Super micro computer surged over 17% in pre-market today, following reports that the company will submit a compliance plan to avoid (delisted) risk. The stock rose over 3% last Friday, with implied volatility soaring to 219.62%, reaching its highest level of the year, and call options saw a surge in demand, accounting for 44% of the total. On the options chain, among the expiring contracts this Friday, the call with a strike price of $23 had the highest volume, reaching 6,000 contracts.
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Top 10 Most Expensive Stocks (Only 1 Gets a Quant Sell)
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.
SPDR S&P Biotech ETF Options Spot-On: On November 15th, 317.65K Contracts Were Traded, With 979.56K Open Interest
On November 15th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 317.65K options for the day, of which put options accounted for 63.21% of the total
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Continuously High Dispersion in the Markets Could Make It a 'Picker's Market'
Shares of Pharmaceutical Companies Are Trading Lower After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Express News | Biotechnology etf plunges! Pharmaceutical stocks collectively decline, with the United States Secretary of Health and Human Services nominee raising market concerns.
Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"